{"title":"增强抗癌免疫的工程细菌疫苗研究进展。","authors":"Wu Liu, Wenjing Chen, Yujie Cai, Yanhua Tang, Tingtao Chen","doi":"10.20517/mrr.2024.75","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in synthetic biology have enabled the development of tumor-targeted live bacterial therapeutics. In a recent study published in <i>Nature</i>, Redenti <i>et al.</i> engineered <i>Escherichia coli</i> Nissle 1917(EcNc<sup>Δlon/ΔompT/LLO+</sup> nAg), which exploits the advantages of living medicines to deliver arrays of tumor-specific neoantigenic epitope in optimal environments, thereby providing a novel strategy for developing effective and durable cancer immunotherapies.</p>","PeriodicalId":94376,"journal":{"name":"Microbiome research reports","volume":"4 1","pages":"14"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977376/pdf/","citationCount":"0","resultStr":"{\"title\":\"Advances in engineered bacteria vaccines for enhancing anti-cancer immunity.\",\"authors\":\"Wu Liu, Wenjing Chen, Yujie Cai, Yanhua Tang, Tingtao Chen\",\"doi\":\"10.20517/mrr.2024.75\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Advances in synthetic biology have enabled the development of tumor-targeted live bacterial therapeutics. In a recent study published in <i>Nature</i>, Redenti <i>et al.</i> engineered <i>Escherichia coli</i> Nissle 1917(EcNc<sup>Δlon/ΔompT/LLO+</sup> nAg), which exploits the advantages of living medicines to deliver arrays of tumor-specific neoantigenic epitope in optimal environments, thereby providing a novel strategy for developing effective and durable cancer immunotherapies.</p>\",\"PeriodicalId\":94376,\"journal\":{\"name\":\"Microbiome research reports\",\"volume\":\"4 1\",\"pages\":\"14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977376/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbiome research reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20517/mrr.2024.75\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbiome research reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/mrr.2024.75","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Advances in engineered bacteria vaccines for enhancing anti-cancer immunity.
Advances in synthetic biology have enabled the development of tumor-targeted live bacterial therapeutics. In a recent study published in Nature, Redenti et al. engineered Escherichia coli Nissle 1917(EcNcΔlon/ΔompT/LLO+ nAg), which exploits the advantages of living medicines to deliver arrays of tumor-specific neoantigenic epitope in optimal environments, thereby providing a novel strategy for developing effective and durable cancer immunotherapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
